Physician profile
John D Smith
NPI 1023054806
$6,500.72
in general payments reported to CMS, 2019-2025
34 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $743 · 2021: $832 · 2022: $892 · 2023: $720 · 2024: $796 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,624.02 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $688.83 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $602.88 | 2019-2024 | |
| Esperion Therapeutics, INC. | $444.47 | 2020-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $332.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $313.61 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.31 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $280.88 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $256.81 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $240.15 | 2022-2025 | Verquvo, Winrevair |
| Amarin Pharma, INC. | $229.39 | 2019-2021 | |
| Abbott Laboratories | $191.48 | 2021-2024 | Mitraclip |
| Cvrx, INC. | $185.86 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.38 | 2019-2024 | Lifevest |
| Heartflow, INC. | $146.10 | 2023 | Ffrct |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $83.52 | 2023-2025 | |
| Inspire Medical Systems, INC. | $72.88 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $41.20 | 2019 | |
| Boston Scientific Corporation | $35.27 | 2019-2024 | Varithena Administration Pack |
| Abiomed | $29.02 | 2025 | |
| G Medical Diagnostic Services, INC. | $25.29 | 2022 | |
| Glaxosmithkline, LLC. | $25.23 | 2025 | Shingrix |
| Edwards Lifesciences Corporation | $18.64 | 2021 | |
| Philips North America LLC | $18.00 | 2025 | Extended Holter |
| Kestra Medical Technology Services, INC. | $17.59 | 2025 | Assure Wcd |
| United Therapeutics Corporation | $17.16 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.74 | 2022 | |
| Normatec Industries, Lp | $16.18 | 2019 | |
| Gilead Sciences, INC. | $15.76 | 2019 | |
| Harmony Biosciences LLC | $15.70 | 2022 | |
| Cmp Pharma, INC. | $13.42 | 2021 | |
| Medtronic Vascular, INC. | $13.10 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.63 | 2019 | |
| Novo Nordisk INC | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.